Iovance Biotherapeutics Targets $1B in Amtagvi Sales, Cuts Costs Amid Growth Initiatives
ByAInvest
Saturday, Sep 20, 2025 2:55 am ET1min read
IOVA--
Iovance Biotherapeutics is targeting $1 billion in sales for its drug Amtagvi (lifileucel) for advanced melanoma, with plans to expand its indication to non-small cell lung cancer and endometrial cancer. The company aims to reduce operating costs by over $100 million in the next four quarters and drive margins through higher manufacturing volume and operational efficiencies.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
LEGAL
Privacy PolicyTerms of UseAIME Terms of UseBrokerage DisclaimerAI Risk DisclosuresEditorial PolicyCONTACT US
Email: support@ainvest.com, editorial@ainvest.com, corrections@ainvest.com, press@ainvest.com, legal@ainvest.com
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet